Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

Avidity Partners Management initiated a new $9.1 million position in Aktis Oncology (AKTS) during Q1 2026, acquiring 468,566 shares. The clinical-stage biotech company develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. With a strong balance sheet of $538.5 million in cash and clinical trials underway, Avidity's investment signals confidence in Aktis' potential as an emerging oncology player, though the company remains early in development.

05/13/2026, 4:10 PM • The Motley Fool

Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology announced that its President and CEO Matthew Roden will present at the BofA Securities Health Care Conference on May 13, 2026. The company is advancing its miniprotein radioconjugate platform for targeted radiopharmaceuticals, with lead programs AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3 across multiple solid tumor indications.

05/06/2026, 8:00 AM • GlobeNewswire

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology announced that clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3, will be presented in two poster presentations at the 2026 ASCO Annual Meeting in May. The FDA cleared IND applications for AKY-2519 in March 2026, enabling the company to proceed with a Phase 1b clinical trial starting mid-2026. AKY-2519 is the company's second clinical-stage miniprotein radioconjugate, following its lead program AKY-1189 targeting Nectin-4.

04/21/2026, 5:00 PM • GlobeNewswire

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, a radiopharmaceutical biotech company, went public on January 9, 2026, raising $318 million in one of the largest recent biotech IPOs. The company specializes in targeted alpha radiopharmaceuticals for cancer treatment. With backing from Eli Lilly (which invested $100 million in shares), a growing nuclear medicine market projected to reach $35 billion by 2030, and an experienced management team, the stock may appeal to long-term investors despite being pre-revenue.

01/14/2026, 11:20 AM • Investing

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aktis Oncology, a clinical-stage oncology company focused on targeted radiopharmaceuticals, completed its upsized IPO on January 12, 2026, raising approximately $365.4 million gross proceeds. The company offered 17.65 million shares at $18.00 per share, with underwriters fully exercising their option to purchase an additional 2.65 million shares. Aktis began trading on Nasdaq under ticker symbol AKTS on January 9, 2026.

01/13/2026, 6:30 AM • Benzinga